Privium Fund Management B.V. Purchases 41,000 Shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)

Privium Fund Management B.V. raised its position in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) by 52.6% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 119,000 shares of the company’s stock after purchasing an additional 41,000 shares during the period. Privium Fund Management B.V.’s holdings in Recursion Pharmaceuticals were worth $804,000 as of its most recent filing with the SEC.

Other hedge funds also recently bought and sold shares of the company. State Street Corp lifted its holdings in Recursion Pharmaceuticals by 47.1% during the third quarter. State Street Corp now owns 12,870,272 shares of the company’s stock worth $84,815,000 after acquiring an additional 4,120,685 shares in the last quarter. Geode Capital Management LLC lifted its holdings in shares of Recursion Pharmaceuticals by 13.7% during the 3rd quarter. Geode Capital Management LLC now owns 5,431,911 shares of the company’s stock valued at $35,803,000 after purchasing an additional 656,003 shares in the last quarter. Institute for Wealth Management LLC. acquired a new position in shares of Recursion Pharmaceuticals in the 4th quarter valued at approximately $3,928,000. Platinum Investment Management Ltd. increased its stake in Recursion Pharmaceuticals by 293.9% during the 4th quarter. Platinum Investment Management Ltd. now owns 733,011 shares of the company’s stock worth $4,955,000 after purchasing an additional 546,929 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. raised its holdings in Recursion Pharmaceuticals by 17.2% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 2,274,003 shares of the company’s stock worth $15,372,000 after buying an additional 333,323 shares during the period. 89.06% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several research firms have recently weighed in on RXRX. Cowen reiterated a “hold” rating on shares of Recursion Pharmaceuticals in a report on Friday, February 28th. Needham & Company LLC reaffirmed a “buy” rating and issued a $11.00 target price on shares of Recursion Pharmaceuticals in a research note on Thursday, February 6th. KeyCorp dropped their price target on Recursion Pharmaceuticals from $12.00 to $10.00 and set an “overweight” rating on the stock in a research note on Wednesday, January 8th. Finally, Leerink Partners reduced their price objective on Recursion Pharmaceuticals from $7.00 to $6.00 and set a “market perform” rating for the company in a research report on Friday, February 28th. Three research analysts have rated the stock with a hold rating and two have given a buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $8.25.

Recursion Pharmaceuticals Stock Down 6.6 %

Recursion Pharmaceuticals stock opened at $6.39 on Wednesday. The company has a current ratio of 4.35, a quick ratio of 4.35 and a debt-to-equity ratio of 0.04. Recursion Pharmaceuticals, Inc. has a 1-year low of $5.60 and a 1-year high of $12.36. The company has a fifty day simple moving average of $7.50 and a 200 day simple moving average of $7.01. The company has a market cap of $2.57 billion, a P/E ratio of -4.18 and a beta of 0.85.

Recursion Pharmaceuticals (NASDAQ:RXRX) last announced its quarterly earnings data on Friday, February 28th. The company reported ($0.53) earnings per share for the quarter, missing the consensus estimate of ($0.36) by ($0.17). Recursion Pharmaceuticals had a negative net margin of 579.52% and a negative return on equity of 76.56%. The company had revenue of $4.60 million during the quarter, compared to the consensus estimate of $19.04 million. During the same quarter in the previous year, the business earned ($0.42) EPS. Recursion Pharmaceuticals’s revenue was down 57.8% on a year-over-year basis. Research analysts anticipate that Recursion Pharmaceuticals, Inc. will post -1.57 earnings per share for the current fiscal year.

Recursion Pharmaceuticals Profile

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.